Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma

Lung Cancer

Volumn 80, Issue 2, 2013, Pages 159-164

  Fujimoto, Daichi ^a   Tomii, Keisuke ^a   Otoshi, Takehiro ^a   Kawamura, Takahisa ^a   Tamai, Koji ^a   Takeshita, Junpei ^a   Tanaka, Kosuke ^a   Matsumoto, Takeshi ^a   Monden, Kazuya ^a   Nagata, Kazuma ^a   Otsuka, Kyoko ^a   Nakagawa, Atsushi ^a   Hata, Akito ^b   Tachikawa, Ryo ^a   Hamakawa, Hiroshi ^a   Katakami, Nobuyuki ^b   Takahashi, Yutaka ^a   Imai, Yukihiro ^a  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

Adenocarcinoma; Epidermal growth factor receptor mutation; High resolution computed tomography; Idiopathic interstitial pneumonia; Interstitial lung disease; Usual interstitial pneumonia

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENE MUTATION; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84875886909     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.01.017     Document Type: Article

References (41)

1. Yamamoto H., Toyooka S., Mitsudomi T. Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer 2009, 63:315-321.
2. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
3. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
4. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
5. Toyooka S., Matsuo K., Shigematsu H., Kosaka T., Tokumo M., Yatabe Y., et al. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res 2007, 13:5763-5768.
6. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97:339-346.
7. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002, 165:277-304.
8. Bouros D., Hatzakis K., Labrakis H., Zeibecoglou K. Association of malignancy with diseases causing interstitial pulmonary changes. Chest 2002, 121:1278-1289.
9. Wynn T.A., Ramalingam T.R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012, 18:1028-1040.
10. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
11. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
12. Milara J., Cortijo J. Tobacco, inflammation, and respiratory tract cancer. Curr Pharm Des 2012.
13. Nathan N., Thouvenin G., Fauroux B., Corvol H., Clement A. Interstitial lung disease: physiopathology in the context of lung growth. Paediatr Respir Rev 2011, 12:216-222.
14. King T.E., Pardo A., Selman M. Idiopathic pulmonary fibrosis. Lancet 2011, 378:1949-1961.
15. Chilosi M., Poletti V., Rossi A. The pathogenesis of COPD and IPF: distinct horns of the same devil?. Respir Res 2012, 13:3.
16. Nagai Y., Miyazawa H., Huqun, Tanaka T., Udagawa K., Kato M., et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005, 65:7276-7282.
17. Riely G.J., Kris M.G., Rosenbaum D., Marks J., Li A., Chitale D.A., et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008, 14:5731-5734.
18. Kim H.R., Shim H.S., Chung J.H., Lee Y.J., Hong Y.K., Rha S.Y., et al. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer 2012, 118:729-739.
19. Murakami Y., Mitsudomi T., Yatabe Y. A screening method for the ALK fusion gene in NSCLC. Front Oncol 2012, 2:24.
20. Goldstraw P., Crowley J., Chansky K., Giroux D.J., Groome P.A., Rami-Porta R., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007, 2:706-714.
21. Ahn M.J., Park B.B., Ahn J.S., Kim S.W., Kim H.T., Lee J.S., et al. Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?. Clin Cancer Res 2008, 14:3860-3866.
22. Lee Y.J., Cho B.C., Jee S.H., Moon J.W., Kim S.K., Chang J., et al. Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer. J Clin Oncol 2010, 28:487-492.
23. Kosaka T., Yatabe Y., Endoh H., Yoshida K., Hida T., Tsuboi M., et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006, 12:5764-5769.
24. Ahrendt S.A., Decker P.A., Alawi E.A., Zhu Yr Y.R., Sanchez-Cespedes M., Yang S.C., et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001, 92:1525-1530.
25. Subramanian J., Govindan R. Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol 2008, 9:676-682.
26. Kawai T., Yakumaru K., Suzuki M., Kageyama K. Diffuse interstitial pulmonary fibrosis and lung cancer. Acta Pathol Jpn 1987, 37:11-19.
27. Vancheri C., Failla M., Crimi N., Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010, 35:496-504.
28. Hironaka M., Fukayama M. Pulmonary fibrosis and lung carcinoma: a comparative study of metaplastic epithelia in honeycombed areas of usual interstitial pneumonia with or without lung carcinoma. Pathol Int 1999, 49:1060-1066.
29. Raeburn B., Spencer H. Lung scar cancers. Br J Tuberc Dis Chest 1957, 51:237-245.
30. Oshikawa K., Sugiyama Y. Serum anti-p53 autoantibodies from patients with idiopathic pulmonary fibrosis associated with lung cancer. Respir Med 2000, 94:1085-1091.
31. Kawasaki H., Ogura T., Yokose T., Nagai K., Nishiwaki Y., Esumi H. p53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis. Hum Pathol 2001, 32:1043-1049.
32. Noguchi M. Stepwise progression of pulmonary adenocarcinoma-clinical and molecular implications. Cancer Metastasis Rev 2010, 29:15-21.
33. Yatabe Y., Kosaka T., Takahashi T., Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 2005, 29:633-639.
34. Yousem S.A. Pulmonary intestinal-type adenocarcinoma does not show enteric differentiation by immunohistochemical study. Mod Pathol 2005, 18:816-821.
35. Inamura K., Satoh Y., Okumura S., Nakagawa K., Tsuchiya E., Fukayama M., et al. Pulmonary adenocarcinomas with enteric differentiation: histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas. Am J Surg Pathol 2005, 29:660-665.
36. Mizushima Y., Kobayashi M. Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis. A review of Japanese cases. Chest 1995, 108:1272-1277.
37. Pappas K. Bronchiolitis and bronchial disorders in interstitial lung disease. Curr Opin Pulm Med 2011, 17:316-324.
38. Kudoh S., Kato H., Nishiwaki Y., Fukuoka M., Nakata K., Ichinose Y., et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008, 177:1348-1357.
39. The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction. Thorax 1999, 54(Suppl. 1):S1-S14.
40. Johkoh T., Muller N.L., Cartier Y., Kavanagh P.V., Hartman T.E., Akira M., et al. Idiopathic interstitial pneumonias: diagnostic accuracy of thin-section CT in 129 patients. Radiology 1999, 211:555-560.
41. Flaherty K.R., King T.E., Raghu G., Lynch J.P., Colby T.V., Travis W.D., et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?. Am J Respir Crit Care Med 2004, 170:904-910.